ConductScience.org, home

Comparison · NCT01190813-0c0166b3

Levodopa/Carbidopa vs Placebo: Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 18 Weeks

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Levodopa/Carbidopa vs Placebo: Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 18 Weeks. Trial comparisons, record NCT01190813-0c0166b3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01190813-0c0166b3

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1510.09050.242wilson
Risk in group 20.04440.01230.148wilson
Risk difference, group 1 minus group 20.107-0.01350.203newcombe hybrid score
Risk ratio, group 1 over group 23.40.80214.4log
Odds ratio, group 1 over group 23.830.82417.8log
Number needed to treat, for one more participant with the outcome on Levodopa/Carbidopa than on Placebo9.37from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Levodopa/CarbidopaLevodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid~Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid~Patching: Two hours of daily patching1386OG000
Group 2PlaceboOral placebo tid~Placebo: Oral placebo tid~Patching: Two hours of daily patching245OG001

Outcome

Type
SECONDARY
Title
Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 18 Weeks
Description
Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.
Time frame
18 weeks after enrollment
Population
The analysis followed the intent-to-treat principle. For missing primary outcome visits (±1 wk), data from a visit 14-27 wks after randomization were used, if available.Multiple imputation(Monte Carlo Markov Chain method) was used for missing 18-wk VA outcomes based on treatment group, baseline VA, and VA scores from completed follow-up visits

Source ClinicalTrials.gov

Trial

Title
Levodopa for the Treatment of Residual Amblyopia
NCT number
NCT01190813
Phases
PHASE3
Conditions
Amblyopia
Interventions
Levodopa/Carbidopa, Placebo, Patching
Lead sponsor
Jaeb Center for Health Research
Results first posted
2015-02-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01190813-0c0166b3